Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches.
Publication
, Journal Article
Strickler, JH; Wu, C; Bekaii-Saab, T
Published in: Cancer Treat Rev
November 2017
Oncogenic mutations in B-type Raf kinase (BRAF) occur in 7-10% of metastatic colorectal cancers (mCRC). Despite recent improvements in survival in the general population of patients with mCRC, patients with BRAF-mutant mCRC continue to have poor response to most systemic therapies, and prognosis remains poor. There is a substantial unmet need for novel therapeutic strategies to treat patients with BRAF-mutant mCRC. This review outlines the epidemiology, molecular pathogenesis, prognosis, and mechanisms of treatment resistance of BRAF-mutated CRC. Additionally, this review highlights novel therapeutic strategies aimed at enhancing response and improving outcomes.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Cancer Treat Rev
DOI
EISSN
1532-1967
Publication Date
November 2017
Volume
60
Start / End Page
109 / 119
Location
Netherlands
Related Subject Headings
- Proto-Oncogene Proteins B-raf
- Oncology & Carcinogenesis
- Neoplasm Metastasis
- Molecular Targeted Therapy
- Humans
- Colorectal Neoplasms
- Biomarkers, Tumor
- Antineoplastic Agents
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Strickler, J. H., Wu, C., & Bekaii-Saab, T. (2017). Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. Cancer Treat Rev, 60, 109–119. https://doi.org/10.1016/j.ctrv.2017.08.006
Strickler, John H., Christina Wu, and Tanios Bekaii-Saab. “Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches.” Cancer Treat Rev 60 (November 2017): 109–19. https://doi.org/10.1016/j.ctrv.2017.08.006.
Strickler JH, Wu C, Bekaii-Saab T. Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. Cancer Treat Rev. 2017 Nov;60:109–19.
Strickler, John H., et al. “Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches.” Cancer Treat Rev, vol. 60, Nov. 2017, pp. 109–19. Pubmed, doi:10.1016/j.ctrv.2017.08.006.
Strickler JH, Wu C, Bekaii-Saab T. Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. Cancer Treat Rev. 2017 Nov;60:109–119.
Published In
Cancer Treat Rev
DOI
EISSN
1532-1967
Publication Date
November 2017
Volume
60
Start / End Page
109 / 119
Location
Netherlands
Related Subject Headings
- Proto-Oncogene Proteins B-raf
- Oncology & Carcinogenesis
- Neoplasm Metastasis
- Molecular Targeted Therapy
- Humans
- Colorectal Neoplasms
- Biomarkers, Tumor
- Antineoplastic Agents
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis